Authors
Latest:
Judy Lieberman, MD, PhD, on the Changing Field of RNA-Based TreatmentsThe endowed chair in cellular and molecular medicine at Boston Children’s Hospital discussed the rapid advancements in RNA-based treatments in the past 2 decades and potential advancements that remain on the horizon.
Latest:
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B PopulationsThe professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed a sub analysis of the HOPE-B trial.
Latest:
Treating Autoimmune Diseases With Smarter Cell TherapiesKaren Walker, chief technology officer, Kyverna Therapeutics, discussed the company’s CAR T-cell and regulatory T-cell technologies.
Latest:
Milan Zdravkovic, MD, PhD, on Using CRISPR-Cas Systems to Target PathogensMilan Zdravkovic, MD, PhD, chief medical officer of SNIPR Biome, discussed the company’s ongoing research on targeting E Coli in the blood with CRISPR-based medication.
Latest:
Liso-cel Shows Survival Benefit in R/R Large B-Cell LymphomaA prespecified interim analysis from the phase 3 TRANSFORM study showed an event-free survival benefit with the second-line therapy.
Latest:
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level With B-VECThe associate professor of dermatology at Stanford University discussed how the May 2023 approval of B-VEC may shift the treatment field for RDEB.
Latest:
Tami John, MD, on the FDA Approvals of Exa-cel and Lovo-celThe clinical associate professor at Stanford Medicine also discussed ongoing trends in sickle cell disease research.
Latest:
Using DNA Nanoplasmids as a Diagnostic Tool in CancerDavid Suhy, PhD, the cofounder and chief scientific officer at Earli, discussed the company’s unique approach to cancer diagnosis.
Latest:
David Shyr, MD, on Incorporating AI Into MedicineThe clinical assistant professor at Stanford Medicine discussed potential applications for machine learning in analyzing data in medicine.
Latest:
CAR T: A Novel Approach for Mantle Cell LymphomaNew treatment options expand management of relapsed or refractory disease.
Latest:
Jacques Galipeau, MD, on Exponential Progress With Cell and Gene TherapyThe Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison discussed the state of cell and gene therapy development.
Latest:
Vinaya Murthy, MS, MPH, on Genetic Counseling Services for Rare DisordersAs we learn more about genomics and identify more genes tied to rare disorders, the role of genetic counselors will become even more critical.
Latest:
Keith Fargo, PhD, on Potential Treatment Avenues for Charcot-Marie-ToothThe chief scientific officer of the CMT Research Foundation discussed investigative cell and gene therapy approaches for treating CMT.
Latest:
Gene Therapy for APOE4 Homozygous Alzheimer DiseaseR. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, discussed Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease.
Latest:
Georg Schett, MD, on Exploring CAR-T for Autoimmune DiseaseThe vice president research and chair of internal medicine at the University of Erlangen – Nuremberg discussed findings from 2 early studies of CD19 CAR T-cell therapy.
Latest:
Dr. Ghosh on the Role of Off-the-Shelf CAR T-Cell Therapy in MyelomaMonalisa Ghosh, MD, discusses the role of off-the-shelf CAR T-cell therapy in patients with multiple myeloma.
Latest:
Axicabtagene Ciloleucel Improves Outcomes in Relapsed/Refractory Follicular LymphomaA comparative analysis of the ZUMA-5 and SCHOLAR-5 trials revealed improvements in outcomes over currently available therapies.
Latest:
Larry Anderson, MD, PhD, on the Evolution of Myeloma Care With Cell TherapyThe professor of internal medicine at UT Southwestern Medical Center shared his perspective on the current landscape of CAR-T cell therapy in the care of patients with myeloma.
Latest:
MeiraGTx announces Fast Track designation by FDA for gene therapy candidate to treat ACHMThe FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).
Latest:
Emerging Data in Diffuse Large B-Cell LymphomaExperts discussed data from trials in lymphoma presented at ASCO 2021.
Latest:
Commentary (Frank): Gene Therapy for Head and Neck CancersLamont et al have presented a very clear and concise review of current gene therapy strategies in the management of squamous cell carcinoma of the head and neck. While the presentation highlighted the most important work to date in this expanding field, it also made reference to some controversies and challenges that we are now facing. With this in mind, I would like to expand on and clarify several points raised by the authors.
Latest:
HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic ImplicationsOverexpression by the HER2 gene plays a significant role in breast cancer pathogenesis, and the phenomenon is commonly regarded as a predictor of a poor prognosis. HER2 overexpression has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and fluoro-uracil) and anthracyclines. Studies of patients with advanced disease demonstrate that, despite the association of HER2 overexpression with poor prognosis, the odds of HER2-positive patients responding clinically to taxanes were greater than three times those of HER2-negative patients. Further studies in preclinical models used combination therapy for breast cancer cells that overexpress HER2, and the use of agents that interfere with HER2 function plus paclitaxel (Taxol) resulted in significant antitumor effects. [ONCOLOGY 11(Suppl):43-48, 1997]
Latest:
HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic ImplicationsOverexpression by the HER2 gene plays a significant role in breast cancer pathogenesis, and the phenomenon is commonly regarded as a predictor of a poor prognosis. HER2 overexpression has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and fluoro-uracil) and anthracyclines. Studies of patients with advanced disease demonstrate that, despite the association of HER2 overexpression with poor prognosis, the odds of HER2-positive patients responding clinically to taxanes were greater than three times those of HER2-negative patients. Further studies in preclinical models used combination therapy for breast cancer cells that overexpress HER2, and the use of agents that interfere with HER2 function plus paclitaxel (Taxol) resulted in significant antitumor effects. [ONCOLOGY 11(Suppl):43-48, 1997]
Latest:
HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic ImplicationsOverexpression by the HER2 gene plays a significant role in breast cancer pathogenesis, and the phenomenon is commonly regarded as a predictor of a poor prognosis. HER2 overexpression has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and fluoro-uracil) and anthracyclines. Studies of patients with advanced disease demonstrate that, despite the association of HER2 overexpression with poor prognosis, the odds of HER2-positive patients responding clinically to taxanes were greater than three times those of HER2-negative patients. Further studies in preclinical models used combination therapy for breast cancer cells that overexpress HER2, and the use of agents that interfere with HER2 function plus paclitaxel (Taxol) resulted in significant antitumor effects. [ONCOLOGY 11(Suppl):43-48, 1997]
